Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)

In brief

Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML

Key facts

Study ID
NCT02629692
Run by
Sun Pharma Advanced Research Company Limited
People needed
124
Starts
2016-06-27
Expected to finish
2025-01-03
Last updated by the study team
2026-05-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.